Patients with thymic epithelial tumors with pleural metastasis or recurrence who undergo extended thymectomy with electrocautery resection of pleural metastases followed by two cycles of hyperthermicHyperthermic Intrathoracic Chemotherapy (HITHOC)
Patients with thymic epithelial tumors with pleural metastasis or recurrence who undergo extended thymectomy with electrocautery resection of pleural metastases followed by two cycles of hyperthermic: Extended thymectomy with electrocautery ablation and resection of pleural metastases. Larger lesions (\>1cm) are thoroughly ablated with electrocautery followed by complete resection. Smaller lesions (≤1cm) that are difficult to resect are thoroughly ablated with electrocautery.
Hyperthermic Intrathoracic Chemotherapy (HITHOC): Two cycles of hyperthermic intrathoracic chemotherapy performed 2-4 days apart using BR-TRG-I device. Chemotherapy solution containing cisplatin (50 mg/m²) and doxorubicin (25 mg/m²) is circulated at 400 mL/min with inflow temperature maintained at 42-43°C for 60 minutes per cycle.
Study summary
The goal of this observational study is to explore the effectiveness of electrocautery resection combined with hyperthermic intrathoracic chemotherapy (HITHOC) in patients with thymic epithelial tumors with pleural metastasis or recurrence. The study aims to:
* Evaluate whether this combined treatment improves event-free survival in patients with pleural metastasis from thymic epithelial tumors
* Assess the rates of grade ≥3 treatment-related adverse events
* Examine how this treatment affects patients' quality of life
Participants will:
* Undergo extended thymectomy with electrocautery resection of pleural metastases
* Receive two cycles of hyperthermic intrathoracic chemotherapy with cisplatin and doxorubicin at 42-43°C, 2-4 days apart
* Complete quality of life questionnaires (EQ-5D) at baseline and regular intervals
* Have regular follow-up visits with imaging and clinical assessments for up to 36 months to monitor for disease recurrence or progression
Eligibility
Sex
ALL
Min age
16 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
* Pathologically confirmed thymic epithelial tumor (TET)
* Imaging evidence of thymic epithelial tumor with pleural dissemination or recurrence, deemed suitable for HITHOC by multidisciplinary thoracic team
* Age ≥16 years and ≤80 years
* American Society of Anesthesiologists (ASA) physical status classification I-II
* Normal major organ function
* No history of other malignancies
* Prior chemotherapy completed \>4 weeks, radiotherapy \>6 weeks, immunotherapy \>6 weeks before enrollment
* No allergy to cisplatin or doxorubicin
* Able to understand the study content and provide informed consent
Exclusion Criteria:
* Evidence of extrathoracic metastasis on imaging or pathological examination
* Myasthenia gravis in unstable phase or acute exacerbation
* Severe systemic comorbidities, such as active infection, poorly controlled diabetes, coagulopathy, bleeding tendency, or ongoing thrombolytic/anticoagulation therapy
* Positive serum pregnancy test or lactation (females)
* History of organ transplantation (including autologous bone marrow transplantation and peripheral blood stem cell transplantation)
* History of peripheral nervous system disease, significant psychiatric disorder, or central nervous system disease
* Currently participating in other clinical trials
Primary outcome measure(s)
Event-Free Survival (EFS) — From treatment initiation to first event (local recurrence, distant metastasis, or death), assessed up to 36 months Time from treatment start to first occurrence of local recurrence, distant metastasis, or death from any cause. Events are assessed through regular imaging and clinical follow-up.
Trial sites (1)
Facility
City
Region
Status
Shanghai General Hospital, Department of Thoracic Surgery
Shanghai
Shanghai Municipality
More Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.